rss
Evid Based Nurs 6:109 doi:10.1136/ebn.6.4.109
  • Treatment

Treatment of hypertension reduces risk of complications in type 2 diabetes

Antihypertensive drugs v placebo or other antihypertensive drugs for hypertension in type 2 diabetes*

Outcomes NRCTs (n) Comparison RRR (95% CI) NNT (CI)
*NRCTs = number of randomised controlled trials. Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article.
Total cardiovascular events 1 (583) Chlorthalidone plus atenolol or reserpine v placebo or usual care 34% (6 to 54) 13 (8 to 100)
1 (492) Nitrendipine v placebo 62% (19 to 80) 13 (8 to 34)
1 (3577) Ramipril v placebo 25% (12 to 36) 20 (15 to 50)
1 (470) Enalapril v nisoldipine 57% (27 to 75) 12 (8 to 25)
1 (380) Fosinopril v amlodipine 51% (5 to 74) 15 (8 to 100)
1 (572) Captopril v thiazide diuretic or β blocker 41% (9 to 62) Not reported
1 (1195) Losartan v atenolol 24% (2 to 42) 20 (10 to 100)
All cause mortality 1 (3577) Ramipril v placebo 24% (8 to 27) 34 (20 to 100)
1 (572) Captopril v thiazide diuretic or β blocker 46% (4 to 69) Not reported
1 (1195) Losartan v atenolol 39% (16 to 55) 17 (10 to 50)
Microvascular end points 1 (3577) Ramipril v placebo 26% (1 to 29) Not significant
1 (1513) Losartan v placebo 21% (5 to 34) Not significant
1 (590) Irbesartan v placebo 70% (39 to 86) 10 (7 to 25)
1 (1715) Irbesartan v amlopidine 23% (7 to 37) 12 (8 to 34)

This Article

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article